Patents by Inventor Mohamad Hamieh

Mohamad Hamieh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Enhanced chimeric antigen receptors and uses thereof
    Patent number: 11932690
    Abstract: The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to novel designs of chimeric antigen receptors (CARs) and engineered immunoresponsive cells comprising the same. The engineered immunoresponsive cells comprising the novel CARs are antigen-directed and have extended persistence without compromising function.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: March 19, 2024
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Michel Sadelain, Judith Feucht, Mohamad Hamieh, Jie Sun, Jorge A. Mansilla-Soto
  • COMBINATIONS OF MULTIPLE CHIMERIC ANTIGEN RECEPTORS FOR IMMUNOTHERAPY
    Publication number: 20220401475
    Abstract: The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward tumor and pathogen antigens. It relates to immunoresponsive cells comprising two or more chimeric antigen receptors (CARs), wherein the CARs comprise different intracellular signaling domains, in particular, the intracellular signaling domains of the CARs comprise different co-stimulatory molecules.
    Type: Application
    Filed: August 18, 2021
    Publication date: December 22, 2022
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Michel Sadelain, Mohamad Hamieh, Judith Feucht
  • FUSION POLYPEPTIDE FOR IMMUNOTHERAPY
    Publication number: 20220133802
    Abstract: The presently disclosed subject matter provides methods and compositions for enhancing immune responses toward tumor and pathogen antigens. It relates to fusion polypeptide that can be expressed in cells (e.g., immunoresponsive cells comprising an antigen-recognizing receptor) to improve the activity and/or efficiency of the cells. In certain embodiments, the fusion polypeptide comprises an extracellular domain and a transmembrane domain of a co-stimulatory ligand, and an intracellular domain of a co-stimulatory molecule.
    Type: Application
    Filed: January 19, 2022
    Publication date: May 5, 2022
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES
    Inventors: Michel Sadelain, Mohamad Hamieh, Anton Dobrin
  • ENHANCED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
    Publication number: 20200317777
    Abstract: The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to novel designs of chimeric antigen receptors (CARs) and engineered immunoresponsive cells comprising the same. The engineered immunoresponsive cells comprising the novel CARs are antigen-directed and have extended persistence without compromising function.
    Type: Application
    Filed: June 24, 2020
    Publication date: October 8, 2020
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Michel Sadelain, Judith Feucht, Mohamad Hamieh, Jie Sun, Jorge A. Mansilla-Soto